Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?

Ranjan, Satish

doi:10.4103/iju.iju_193_20

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radionuclides that concentrated in cells, close to nearby nucleus, can cause DNA damage and effectively, its apoptosis of the cells by ionizing radiation. Because of this fact, PSMA was chosen as a biomarker in radionuclide therapy (18)(19)(20).…”

Section: Molecular Structure and Biological Function Of The Prostate-...mentioning

confidence: 99%

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

Szponar,

Petrasz,

Brzeźniakiewicz-Janus

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionRadio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature on the therapeutic isotopes specific for PSMA.MethodsWe performed a scoping literature review of PubMed from January 1996 to December 2022.Results98 publications were selected for inclusion in this review. The studies contained in publications allowed to summarize the data on pharmacokinetics, therapeutic effects, side effects and the medical use of 225Ac and 177Lu radionuclides. The review also presents new research directions for specific PSMA radionuclides.ConclusionRadioligand targeted therapy is a new and promising concept where Lu-177-PSMA-617 have promising outcomes in treatment according to standard of care.

show abstract

Section: Molecular Structure and Biological Function Of The Prostate-...mentioning

confidence: 99%

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

Szponar,

Petrasz,

Brzeźniakiewicz-Janus

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The PSMA receptor has an internalization process that allows endocytosis of bound proteins on the cell surface into an endosomal compartment, which allows PSMA labelled radioisotopes to be concentrated within the cell. The density of expression of this transmembrane receptor on prostate cancer cells further increases depending on the Gleason score of the prostate cancer, and in castrate-resistant prostate cancers, which makes it an ideal target for radionuclide therapy (16,17). A small molecule that specifically binds to the PSMA is commercially available as PSMA-11 and PSMA-617.…”

Section: Lu-psmamentioning

confidence: 99%

Theranostics in Metastatic Castrate Resistant Prostate Cancer

Vorster

Sathekge

2021

Prostate Cancer

View full text Add to dashboard Cite

Despite advances in the treatment of localized prostate cancer, many patients progress to metastatic castration-resistant prostate cancer with limited median survival benefits, and significant morbidity. Therefore, efforts to explore new therapeutic modalities for metastatic castration-resistant prostate cancer are urgently needed. A theranostic approach in oncology is based on the principle of imaging a particular molecular target with a diagnostic radioisotope, and then substituting it with a therapeutic isotope to treat a patient who demonstrates sufficient target expression on diagnostic images. Radioisotope pairs are usually chosen in such a way that their physical and chemical properties are similar to ensure the therapeutic agent will be distributed in the same way as the diagnostic agent. This chapter outlines the most recent advances in the use of prostate specific membrane antigen (PSMA) in theranostics with emphasis on 177 Lu-PSMA, 225 Ac-PSMA and 223 Ra-dicloride. The clinical utility of these radioisotopes along with their limitations and future perspectives are discussed.

show abstract

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?

Cited by 2 publications

References 7 publications

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

Theranostics in Metastatic Castrate Resistant Prostate Cancer

Contact Info

Product

Resources

About